CYP17 — Drug Target

All drugs that target CYP17 — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Androgen biosynthesis inhibitor · CYP17 inhibitor

Marketed (1)

• Abiraterone Acetate · Pfizer · Androgen biosynthesis inhibitor · Oncology
  Abiraterone is an androgen biosynthesis inhibitor that targets CYP17 to reduce androgen production in prostate cancer cells.

Phase 3 pipeline (1)

• SoluMatrix™ Abiraterone Acetate · GU Research Network, LLC · CYP17 inhibitor · Oncology
  Abiraterone acetate is a CYP17 inhibitor that blocks the production of androgens, such as testosterone, in the body.

Phase 2 pipeline (3)

• Abiraterone acetate standard dose · Assistance Publique - Hôpitaux de Paris · CYP17 inhibitor · Oncology
  Inhibits CYP17, an enzyme involved in the production of androgens.
• Abiraterone acetate tablets · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · CYP17 inhibitor · Oncology
  CYP17 inhibitor
• Abiraterone - Usual · Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · CYP17 inhibitor · Oncology
  Abiraterone is an androgen biosynthesis inhibitor that blocks the production of testosterone in the body.

Phase 1 pipeline (4)

• Abiraterone acetate suspension Formulation 1 · Cougar Biotechnology, Inc. · CYP17 inhibitor · Oncology
  Androgen receptor inhibitor
• Abiraterone: Treatment A · Janssen Research & Development, LLC · CYP17 inhibitor · Oncology
  Inhibits CYP17, a key enzyme in the biosynthesis of androgens.
• Abiraterone acetate MTD · Cougar Biotechnology, Inc. · CYP17 inhibitor · Oncology
  Androgen receptor inhibitor
• Abiraterone: Treatment C · Janssen Research & Development, LLC · CYP17 inhibitor · Oncology
  CYP17 inhibitor